We have investigated the fact that TSRP inhibits the PI3K/Akt/mTOR pathway to prevent bone metastasis of NSCLC with PI3K mutation and primary immune checkpoint resistance. This evidence concerns the gene MTOR and non-small cell lung carcinoma.